Search
PTI-801
go.drugbank.com/drugs/DB05300InvestigationalIt is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. … PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone.
MBT-0312
go.drugbank.com/drugs/DB05880ExperimentalMediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
NCX 1015
go.drugbank.com/drugs/DB05825ExperimentalNCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.
Talarozole
go.drugbank.com/drugs/DB13083InvestigationalTalarozole has been investigated for the treatment of Psoriasis and Cutaneous Inflammation.
SLV319
go.drugbank.com/drugs/DB05077ExperimentalSLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.
Etamivan
go.drugbank.com/drugs/DB08989ApprovedWithdrawnEtamvin is a respiratory stimulant drug similar to nikethamide. It is no longer used in the United States.
Namilumab
go.drugbank.com/drugs/DB13037InvestigationalNamilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
UM-171
go.drugbank.com/drugs/DB19449InvestigationalUM-171 is a pyrimidoindole derivative that is an agonist of ex vivo hematopoietic stem cell expansion and thus supports the expansion of hematopoietic stem cells.[A264868, A264873]
Bicifadine
go.drugbank.com/drugs/DB04889InvestigationalBicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. … Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain.
Categories: Monoamine Oxidase A SubstratesAZD2389
go.drugbank.com/drugs/DB22104InvestigationalNCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants). … AZD2389 is an investigational small molecule inhibitor of fibroblast activation protein (FAP).[L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g.